Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nutritional Regimes Enriched with Antioxidants as an Efficient Adjuvant for IBD Patients under Infliximab Administration, a Pilot Study.
Liso M, Sila A, Verna G, Scarano A, Donghia R, Castellana F, Cavalcanti E, Pesole PL, Sommella EM, Lippolis A, Armentano R, Giudetti AM, Vergara D, Campiglia P, Sardone R, Curlo M, Mastronardi M, Petroni K, Tonelli C, Santino A, Chieppa M. Liso M, et al. Among authors: donghia r. Antioxidants (Basel). 2022 Jan 8;11(1):138. doi: 10.3390/antiox11010138. Antioxidants (Basel). 2022. PMID: 35052642 Free PMC article.
Variations in Circulating Levels of Angiopoietin-2 Over Time Are Predictive of Ramucirumab-Paclitaxel Therapy Outcome in Advanced Gastric Cancer: Results of Prospective Study.
D'Alessandro R, Refolo MG, Schirizzi A, De Leonardis G, Donghia R, Guerra V, Giannelli G, Lolli IR, Laterza MM, De Vita F, Messa C, Lotesoriere C. D'Alessandro R, et al. Among authors: donghia r. Front Oncol. 2022 Apr 6;12:862116. doi: 10.3389/fonc.2022.862116. eCollection 2022. Front Oncol. 2022. PMID: 35463372 Free PMC article.
Corrigendum: Variations in circulating levels of angiopoietin-2 over time are predictive of ramucirumab-paclitaxel therapy outcome in advanced gastric cancer: results of prospective study.
D'Alessandro R, Refolo MG, Schirizzi A, De Leonardis G, Donghia R, Guerra V, Giannelli G, Lolli IR, Laterza MM, De Vita F, Messa C, Lotesoriere C. D'Alessandro R, et al. Among authors: donghia r. Front Oncol. 2023 Apr 14;13:1187014. doi: 10.3389/fonc.2023.1187014. eCollection 2023. Front Oncol. 2023. PMID: 37124498 Free PMC article.
Plasma Bacterial DNA Load as a Potential Biomarker for the Early Detection of Colorectal Cancer: A Case-Control Study.
Giacconi R, Donghia R, Arborea G, Savino MT, Provinciali M, Lattanzio F, Caponio GR, Coletta S, Bianco A, Notarnicola M, Bonfiglio C, Passarino G, D'Aquila P, Bellizzi D, Pesole PL. Giacconi R, et al. Among authors: donghia r. Microorganisms. 2023 Sep 21;11(9):2360. doi: 10.3390/microorganisms11092360. Microorganisms. 2023. PMID: 37764204 Free PMC article.
VEGFA Status as a Predictive Marker of Therapy Outcome in Metastatic Gastric Cancer Patients Following Ramucirumab-Based Treatment.
Schirizzi A, Arshadi A, Tolomeo D, Schirosi L, Valentini AM, De Leonardis G, Refolo MG, Donghia R, Storlazzi CT, Zito A, Ricci AD, Vallarelli S, Ostuni C, Bencivenga M, De Manzoni G, Messa C, Armentano R, Giannelli G, Lotesoriere C, D'Alessandro R. Schirizzi A, et al. Among authors: donghia r. Biomedicines. 2023 Oct 7;11(10):2721. doi: 10.3390/biomedicines11102721. Biomedicines. 2023. PMID: 37893095 Free PMC article.
Galad Score as a Prognostic Marker for Patients with Hepatocellular Carcinoma.
Cagnin S, Donghia R, Martini A, Pesole PL, Coletta S, Shahini E, Boninsegna G, Biasiolo A, Pontisso P, Giannelli G. Cagnin S, et al. Among authors: donghia r. Int J Mol Sci. 2023 Nov 18;24(22):16485. doi: 10.3390/ijms242216485. Int J Mol Sci. 2023. PMID: 38003675 Free PMC article.
Women in LOVe: Lacto-Ovo-Vegetarian Diet Rich in Omega-3 Improves Vasomotor Symptoms in Postmenopausal Women. An Exploratory Randomized Controlled Trial.
Rotolo O, Zinzi I, Veronese N, Cisternino AM, Reddavide R, Inguaggiato R, Leandro G, Notarnicola M, Tutino V, De Nunzio V, De Leonardis G, Guerra V, Donghia R, Fucilli F, Licinio R, Mastrosimini A, Rinaldi CCM, Daddabbo T, Giampaolo N, Iacovazzi PA, Giannico S, Caruso MG. Rotolo O, et al. Among authors: donghia r. Endocr Metab Immune Disord Drug Targets. 2019;19(8):1232-1239. doi: 10.2174/1871530319666190528101532. Endocr Metab Immune Disord Drug Targets. 2019. PMID: 31132980 Clinical Trial.
106 results